Description
This section will provide an overview and understanding of:
- Key stakeholders in the French retail & hospital market
- Pricing and Reimbursement timelines in France
- Key determinants, such as the SMR and ASMR, influencing the reimbursement status and pricing potential of an asset
- Recent trends within SMR and ASMR assessments
- Extra funding pathways for hospital products
- Opportunities for early access and reimbursement in France via the ATU program
- Analogue examples of drugs with ATU pathway
- Illustrative analogue cases showcasing assessment and pricing trends for specific therapeutic areas